Presentation
Posters
On
November 22, 2019, DelMar Pharmaceuticals, Inc. (the “Company”) presented two posters at the Society for Neuro-Oncology
annual meeting in Phoenix, Arizona. Copies of the posters are attached as Exhibits 99.1 and 99.2 hereto.
Post-Effective
Amendments
As
previously disclosed, on June 25, 2019, the Company filed a registration statement with the Securities and Exchange Commission
(the “SEC”) on Form S-1 (File No. 333-232332) (as amended, the “Resale Registration Statement”) covering
the resale of 760,500 shares of its common stock, par value $0.001 per share (the “Common Stock”), issuable upon the
exercise of common warrants by certain selling stockholders. The Resale Registration Statement was originally declared effective
by the SEC on July 16, 2019.
Also
as previously disclosed, on August 1, 2019, the Company filed a registration statement with the SEC on Form S-1 (File
No. 333-232931) (as amended, the “Primary Registration Statement” and, together with the Resale Registration
Statement, the “Registration Statements”). The Primary Registration Statement was originally declared effective
by the SEC on August 14, 2019. The Primary Registration Statement originally covered a primary offering of (i) 4,095,000 shares
of Common Stock, pre-funded warrants to purchase an aggregate of 2,655,000 shares of Common Stock and (ii) common warrants to
purchase an aggregate of 6,750,000 shares of Common Stock. On August 16, 2019, the Company closed on the sale of (i) 4,895,000
shares of Common Stock, (ii) pre-funded warrants to purchase an aggregate of 2,655,000 shares of Common Stock and (iii) common
warrants to purchase an aggregate of 7,762,500 shares of Common Stock, including 800,000 shares of Common Stock and warrants to
purchase an aggregate of 1,012,500 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters’
option to purchase additional securities.
On
November 15, 2019, the Company filed a Post-Effective Amendment No. 1 to the Resale Registration Statement (the “Resale
Post-Effective Amendment”) and a Post-Effective Amendment No. 2 to the Primary Registration Statement (the “Primary
Post-Effective Amendment” and, together with the Resale Post-Effective Amendment, the “Post-Effective Amendments”)
in order to incorporate by reference the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 that
was filed with the SEC on September 9, 2019 and the Company’s Quarterly Report on Form 10-Q for the quarter ended September
30, 2019 that was filed with the SEC on November 13, 2019 and to make certain corresponding changes in each Registration Statement.
No
additional securities are being registered under the Post-Effective Amendments. The Post-Effective Amendments were declared effective
by the SEC on November 20, 2019.
At
September 30, 2019, the Company had cash and cash equivalents on hand of approximately $8.06 million, which are expected to be
sufficient to fund the Company’s planned operations into the fourth quarter of calendar year 2020.